Oppenheimer analyst Jason Helfstein downgrades Snap (NYSE:SNAP) from Outperform to Perform.
Acurx Pharmaceuticals Q4 EPS $(0.28) Beats $(0.35) Estimate; Cash Position Of $9.1M
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.35) by 20 percent. This is a 27.27 percent decrease over losses of $(0.22) per share
